My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 905

    1.

    Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

    Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, Gallwitz B.

    Diabetes. 2004 Mar;53(3):654-62.PMID: 14988249 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.

    J Clin Invest. 1993 Jan;91(1):301-7.PMID: 8423228 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

    Nauck MA, El-Ouaghlidi A, Gabrys B, Hücking K, Holst JJ, Deacon CF, Gallwitz B, Schmidt WE, Meier JJ.

    Regul Pept. 2004 Nov 15;122(3):209-17.PMID: 15491793 [PubMed - indexed for MEDLINE]Related articles

    4.

    Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

    Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ.

    Diabetes. 2001 Mar;50(3):609-13.PMID: 11246881 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Erythromycin antagonizes the deceleration of gastric emptying by glucagon-like peptide 1 and unmasks its insulinotropic effect in healthy subjects.

    Meier JJ, Kemmeries G, Holst JJ, Nauck MA.

    Diabetes. 2005 Jul;54(7):2212-8.PMID: 15983224 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs.

    Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ.

    J Endocrinol. 2002 Feb;172(2):355-62.PMID: 11834453 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Release of glucagon-like peptide 1 (GLP-1 [7-36 amide]), gastric inhibitory polypeptide (GIP) and insulin in response to oral glucose after upper and lower intestinal resections.

    Nauck MA, Siemsglüss J, Orskov C, Holst JJ.

    Z Gastroenterol. 1996 Mar;34(3):159-66.PMID: 8650968 [PubMed - indexed for MEDLINE]Related articles

    9.

    alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.

    Diabet Med. 2005 Apr;22(4):470-6.PMID: 15787675 [PubMed - indexed for MEDLINE]Related articles

    10.

    Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

    Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB.

    Eur J Endocrinol. 1996 Oct;135(4):425-32.PMID: 8921824 [PubMed - indexed for MEDLINE]Related articles

    11.

    Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

    Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W.

    J Clin Endocrinol Metab. 1993 Apr;76(4):912-7.PMID: 8473405 [PubMed - indexed for MEDLINE]Related articles

    12.

    Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

    Regul Pept. 2003 Jul 15;114(2-3):115-21.PMID: 12832099 [PubMed - indexed for MEDLINE]Related articles

    13.

    Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).

    Ranganath L, Schaper F, Gama R, Morgan L, Wright J, Teale D, Marks V.

    Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):390-4.PMID: 10634963 [PubMed - indexed for MEDLINE]Related articles

    14.

    Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

    Meier JJ, Gallwitz B, Askenas M, Vollmer K, Deacon CF, Holst JJ, Schmidt WE, Nauck MA.

    Diabetologia. 2005 Sep;48(9):1872-81. Epub 2005 Jul 12.PMID: 16010522 [PubMed - indexed for MEDLINE]Related articles

    15.

    Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.

    Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ.

    Diabetes. 2008 Mar;57(3):678-87. Epub 2007 Dec 5.PMID: 18057091 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Insulin secretion and incretin hormones after oral glucose in non-obese subjects with impaired glucose tolerance.

    Rask E, Olsson T, Söderberg S, Holst Jj J, Tura A, Pacini G, Ahrén B.

    Metabolism. 2004 May;53(5):624-31.PMID: 15131768 [PubMed - indexed for MEDLINE]Related articles

    17.

    Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia.

    Toft-Nielsen M, Madsbad S, Holst JJ.

    Diabetologia. 1998 Oct;41(10):1180-6.PMID: 9794105 [PubMed - indexed for MEDLINE]Related articles

    18.

    The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

    J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.PMID: 14557471 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.

    Mentlein R, Gallwitz B, Schmidt WE.

    Eur J Biochem. 1993 Jun 15;214(3):829-35.PMID: 8100523 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

    Greenfield JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, Reimann F, Holst JJ, Gribble FM.

    Am J Clin Nutr. 2009 Jan;89(1):106-13. Epub 2008 Dec 3.PMID: 19056578 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity